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ABSTRACT: Cases of diabetes are on the rise in almost every population and epidemiological studies 
suggest that without proper prevention and control measures, prevalence of the disease will continue to 
increase globally. The aim of the current study was to investigate the effect of camel milk supplementation on 
serum glucose, lipid profile and body weight of alloxan-induced diabetic rats. Rats were rendered diabetic by 
intravenous injection of alloxan (80mg/kg body weight). Diabetic rats showed significantly higer blood glucose 
levels (9.68±1.36 mmol/L). Treatment with camel milk significantly decreases blood glucose levels 
(5.33±0.46) p<0.05 compared to control. There was a significant increase (p<0.05) in serum total cholesterol, 
triglyceride, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, and a significant 
decrease (p<0.05) in high density lipoprotein cholesterol in diabetic untreated rats as compared with control 
group. However, a significant decrease (p<0.05) in total cholesterol, triglyceride, low density lipoprotein 
cholesterol, very low density lipoprotein cholesterol, and a significant increase (p<0.05) in high density 
lipoprotein cholesterol was observed in diabetic treated with camel milk group as compared with diabetic 
untreated group. No significant change in body weights were observed in all experimental groups during the 
period of the experiment. The current study demonstrates the efficacy of camel milk in management of 
diabetes in alloxan induced diabetic rats. This suggests that camel milk may have important implication in the 
management of diabetes. Further studies are required to elucidate the safety as well as the mechanism of 
action. 
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INTRODUCTION  
Diabetes is the most common metabolic disorder 
worldwide and its pathogenesis involves insufficient 
insulin secretion and/or resistance to the action of 
insulin (Goldstein 2003). The defect in insulin 
secretion and/or action leads to various metabolic 
defects that include hyperglycaemia, dyslipidemia, 
and other forms of tissue damage by several 
mechanisms (Muoio, 2008). There is an increasing 
evidence of diabetes in almost every population 
worldwide and epidemiological studies suggests that 
without proper prevention and control programmes, 
prevalence of the disease will continue to increase 
globally (Alberti et al., 2007). Diabetes affects people 
all over the world and it has been shown that people 
with a family history of diabetes are at high risk of 
developing diabetes (IDF, 2009). Diabetes can be 
induced chemically using many compounds such as 
alloxan monohydrate. Alloxan-induced diabetes 
mellitus is caused by selective pancreatic beta cell 
toxicity (Rerup, 1970; Sakudelski, 2001). Rats, 
rabbits and dogs are quite sensitive to alloxan 
(Typerg et al., 2001).  
 
Diabetes is difficult to cure. However, management of 
the disease concentrates on keeping blood sugar 
levels as close to normal without presenting 
unwarranted patient risk (WHO, 2006). This can be 
achieved with close dietary management, exercise, 
and the use of appropriate medications. The currently 
marketed antidiabetic drugs produce or are 
associated with negative patient outcomes. For 
example, thiazolidinediones (TZDs) the most potent 
antidiabetic drugs are associated with adverse patient 
outcome. Some of the adverse side effects of TZDs 
include weight gain due to fluid retention or oedema 
(Lebovitz and Banerji, 2001), inhibition of vascular 
smooth muscles and endothelial cells growth and 
migration (Hsueh and Law, 2001), risk of congestive 
heart failure, increase risk of myocardial infarction 
and death from cardiovascular causes (Nissen and 
Wolski, 2007). These and possible high cost of these 
drugs make the search for cheaper, effective and 
safer hypoglycaemic agents worthwhile.  
 
Treatment of diabetes was based on compounds 
derived from natural products and other types of 
traditional foods before the advent of insulin therapy. 
Data on the efficacy and safety of these natural 
products is scarce. The search for effective and safer 
hypoglycaemic agents is now an active area of 
research. 
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The use of camel milk as medicine has been known 
since ancient times. The milk has been shown to 
possess hypoallergenic (Shabo et al., 2005), and 
anti-diabetic properties (Agrawal et al., 2003). In 
addition, Agrawal et al., (2005) reported that camel 
milk has an adjuvant effect to insulin therapy in 
controlling diabetes due to the presence of high 
levels of insulin or insulin like protein.   
 
Camel milk from different part of the world may have 
different therapeutic properties because the 
composition of the milk depends on its feed and 
species (Farah et al., 1992). Other studies also 
reported variations in certain essential mineral 
elements and important vitamins (Malik et al., 2008) 
that are important in management of diabetes and 
other metabolic disorders. It is therefore the aim of 
the present research to investigate the efficacy of 
camel milk obtained from Sokoto, North-West Nigeria 
in the management of diabetes. 
 
MATERIALS AND METHODS 
All chemicals and reagents used were of analytical 
grade. Glucose oxidase Kit, Total Cholesterol assay 
kit, Triglyceride assay kit and HDL-C assay kit were 
all products of Randox Laboratories, Switzerland. 
Fresh camel milk samples were obtained from a 
camel herd (Camelus dromedaries) in Sokoto-
Nigeria.  
 
Experimental Design  
Animals: Fifteen clinically normal wistar albino rats of 
both sexes weighing between 160-200g were used 
for the study. The rats were purchased from the 
Department of Biological Science, Usmanu Danfodiyo 
University, Sokoto, Nigeria and were allowed to 
acclimatize before the commencement of the 
experiment. Rats were fed with pelletized growers’ 
feed (Vital feed, Jos, Nigeria). The diet contains 54% 
carbohydrates, 13% fat, 10% proteins, 20% fibre, 2% 
normal supplement and 1% vitamin and water. The 
rats were allowed access to water ad libitum before 
and during the experimental period. 
 
Induction of Diabetes: Induction of diabetes was by 
intravenous injection of alloxan (Black et al., 1980). 
Fresh solution of alloxan was prepared prior to 
experiment and rats were administered 80mg/Kg 
body weight of the prepared solution. After one week 
of alloxan injection, diabetes was confirmed through 
the measurement of blood glucose levels from tail 
vein blood using glucometer (Prestige). Rats with 
blood glucose concentration ≥8.0 mmol/L were 
considered for the experiment. 
 
Grouping: The animals were grouped into 3 groups 
of five rats each. Group 1 (non diabetic-non 
supplemented) to which no alloxan induction no milk 
supplementation. Group 2 (diabetic-non 
supplemented) to which diabetes was induced but no 
milk supplementation. Group 3 (diabetic-treated) to 
which diabetes was induced and supplemented with 
fresh camel milk. Each rat in Group 3 was treated 
with 1ml of camel milk daily using 1ml syringe for oral 
administration for 2 weeks. The dose was then 
increased to 2ml for additional 2 weeks.  
 
Blood and Serum Collection: After four weeks of 
the treatment, the rats were fasted for 12 hours, 
anesthetized using chloroform and then sacrificed by 
decapitation using razor blade. Blood sample was 
collected through cardiac puncture in clean dry test 
tubes (without any anticoagulant) and allowed to clot 
at room temperature for 30 minutes. The serum was 
separated by centrifugation at 4000g for 10 minutes 
and were saved in aliquots and stored at -20ºC for 
further analysis.  
 
Biochemical Analysis   
Biochemical analytes were estimated using 
commercially available kits as follows. Blood glucose 
level was determined using glucose oxidase method 
(Trinder,1969), Serum total cholesterol (TC) (Allain et 
al., 1974), serum triglycerides (TAG) (Tietz, 1990), 
serum High Density Lipoprotein (HDL-C) (Burstein et 
al., 1980), Serum Low Density Lipoprotein cholesterol 
(LDL-C) (Friedwald et al., 1972) and serum Very Low 
Density Lipoprotein cholesterol (VLDL-C) (Friedwald 
et al., 1972). Atherogenic index was calculated as 
ratio of LDL-C to HDL-C (Abott et al., 1988).  
 
RESULTS AND DISCUSSION 
Effect of Camel Milk Supplementation on Body 
Weight: Body weight of rats in control group was 
266.25±25.49 g, diabetic untreated 242.33±9.56 g, 
and in diabetic treated was 253.45±22.20 g. There 
were no statistically significant difference (p>0.05) in 
the body weights of all the groups. 
 
Effect of Camel Milk Supplementation on Serum 
Glucose Levels of alloxan-induced diabetic Rats 
Blood glucose level in camel milk treated group when 
compared to diabetic untreated was 5.33±0.46 and 
9.68±1.36 mmol/L respectively. As shown in Figure 
1, giving camel milk to alloxan-induced diabetic rats 
was associated with decrease in blood glucose 
levels.  
 
The significant decrease in blood glucose level in 
diabetic rats treated with camel milk could be due to 
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the reported high levels of insulin or insulin like 
protein in camel milk (Farah 1993; Agrawal et al., 
2003). Other studies attributed hypoglycaemic effect 
of camel milk by its potential to either increase the 
effect of insulin or by increasing the release of insulin 
from the pancreatic beta-cells (Sboui et al., 2010). 
 
Table 1: Initial and final body weight of alloxan-
induced diabetic rats treated with or without 
camel milk. 
Groups Body weight (g) 
 Initial  Final  
Group 1 245.20±17.89 266.25±25.49 
Group 2 251.70±10.15 242.33±9.56 
Group 3 265.00±24.13 253.45±22.20 
Values are mean ± SEM of body weight of alloxan induced 




Figure 1: Serum blood glucose concentration 
(mmol/L) of alloxan-induced diabetic rats 
supplemented with camel milk. 
Values are expressed as mean±SD. *denotes P<0.05 
compared to diabetic untreated. Group 1=control; Group 
2=diabetic non supplemented; Group 3=diabetic 
supplemented 
 
Effect of Camel Milk Supplementation on serum 
Lipid Profile of alloxan-induced Diabetic Rats 
The effect of camel milk supplementation on serum 
lipid profile is presented in Table 2. There was a 
significant increase (p<0.05) in serum total 
cholesterol (TC), triglycerides (TAG), low density 
lipoprotein cholesterol (LDL-C), very low density 
lipoprotein cholesterol (VLDL-C), and a significant 
decrease (p<0.05) in high density lipoprotein 
cholesterol (HDL-C) in diabetic untreated rats as 
compared with control group. However, a significant 
decrease (p<0.05) in TC, TAG, LDL-C, VLDL-C, and 
a significant increase (p<0.05) in HDL-C was 
observed in diabetic treated with camel milk group as 
compared with diabetic untreated group. 
 
There is clear evidence of the negative impact of 
diabetes on the prevalence, severity and prediction of 
cardiovascular diseases. Several epidemiological 
studies have shown a consistent association between 
hyperglycemia and cardiovascular diseases (Balku et 
al., 2004). In addition, insulin deficiency as a result of 
diabetes leads to abnormalities in lipid metabolism 
(Arkkila et al., 2001). In this study, alloxan-induced 
diabetic rats showed increased hypercholesterolemia, 
hypertrigly-ceridemia and decreased levels of HDL-C 
(Table 2). These results are in agreement with 
previous reports (Mathe 1995; Hassan and Emam, 
2012). Our result shows that treatment with camel 
milk is associated with a significant decrease in 
triglycerides level compared with untreated (Table 2). 
Hypertriglyceridemia is a common feature of 
diabetes. Lipoprotein lipase is the enzyme that 
hydrolyses triglycerides. However, insulin was shown 
to activate this enzyme (Arrkila et al., 2001) and 
because of the high levels of insulin in camel milk, 
this may be a possible cause of the reduction of the 
triglycerides levels in the treated group.  
 
Administration of camel milk to diabetic rats brought 
about a significant decrease in circulating LDL-C and 
total cholesterol (Table 2). Under normal conditions, 
LDL-C is cleared from the circulation by reuptake in 
the liver through receptor mediated uptake (Tiwari et 
al., 2008). A well-known risk factor for the 
development of diabetes and cardiovascular disease 
is lipid accumulation in non-adipose tissues (van 
Herpen & Schrauwen-Hinderling, 2008). Thus, the 
increase in LDL-C seen in diabetic rats may be due to 
increased mobilization of free fatty acids, as well as 
defect in LDL-C receptors. Meanwhile, there was a 
significant increase in HDL-C levels in rats treated 
with camel milk compared to untreated (Table 2). 
Excess cholesterol is removed from the circulation by 
HDL (Stermerman, 2000) and it is regarded as good 
cholesterol due to the fact that it is associated with 
decreased tendency of development of 
atherosclerosis (Rader, 2006) a risk factor for the 
development of diabetes.    
 
Effecct of camel milk supplementation on 
atherogenic index  
The result of the effect of camel milk supplementation 
on atherogenic index is presented in Table 2. The 
result shows that camel milk’s supplementation is 
associated with a decrease in atherogenic index 
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Table 2: Serum lipid profiles & Atherogenic index of alloxan-induced diabetic rats supplemented with camel milk  
Parameters Group 1 Group 2 Group 3 
TC (mg/dl) 208.29±23.11 479.41±57.56* 264.78±30.27˟ 
TAG (mg/dl) 110.00±14.14 650.00±104.08* 192.00±19.85˟ 
HDL-C (mg/dl) 152.57±17.19 114.69±4.86* 220.82±14.59˟ 
LDL-C (mg/dl) 33.72±4.24 234.72±37.26* 5.59±2.56˟ 
VLDL-C (mg/dl) 22.00±2.83 130.00±20.82* 38.4±3.97˟ 
Atherogenic index  0.22 2.05 0.025 
Values are means ± S.E. (*denotes P<0.05 compared to control; ˟ denotes P<0.05 compared to diabetic untreated). 
 
CONCLUSION 
The current study demonstrates the efficacy of camel 
milk in management of diabetes in alloxan induced 
diabetic rats. This suggests that camel milk 
consumption may have important implication in the 
management of diabetes in human. Further studies 
are required to elucidate the safety as well as the 
mechanism of action of the agent(s) in camel’s milk.    
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